ABVC Biopharma Inc（ABVC）股票分析

AI 分析 of ABVC Biopharma Inc (ABVC)

持有

ABVC Biopharma Inc is currently trading at $0.98, which is significantly lower than its 52-week high of $3.06, indicating a potential undervaluation. However, the stock has a low RSI of 36.75, suggesting it is nearing oversold territory, but it has also experienced a substantial year-to-date decline of 55.25%. The company has reported no revenue for several quarters, and its forward P/E ratio is 0, indicating uncertainty about future earnings. The main risk is the negative net income trend, with losses reaching -$3.56 million in Q4 2025. Therefore, while there are signs of potential recovery, the lack of revenue and ongoing losses suggest a cautious approach is warranted.

估值指標

ABVC Biopharma Inc（ABVC）目前預期本益比為 0.00，5 年平均預期本益比為 -1.92。

預期本益比

合理

5 年均值 P/E

-1.92

目前P/E

0.00

高估

1.06

低估

-4.90

預期 EV/EBITDA

嚴重低估

5 年均值 EV/EBITDA

0.00

目前EV/EBITDA

0.00

高估

0.00

低估

0.00

預期股價營收比

合理

5 年均值 P/S

116.68

目前P/S

0.00

高估

431.38

低估

-198.03

Alphio AI 對 ABVC 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重（25 / 50 / 25），不構成保證。

樂

樂觀

樂觀 · 25%ABVC

$3.35

情境價格

基

基準

基準 · 50%ABVC

$3.17

情境價格

悲

悲觀

悲觀 · 25%ABVC

$2.76

情境價格

ABVC 常見問題 —— 由 Alphio AI 解答

ABVC Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of new drugs and medical devices, all of which are derived from plants. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV-1501, and ABV-1701. The Company is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine. ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. It has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

ABVC Biopharma Inc is currently trading at $0.98, which is significantly lower than its 52-week high of $3.06, indicating a potential undervaluation. However, the stock has a low RSI of 36.75, suggesting it is nearing oversold territory, but it has also experienced a substantial year-to-date decline of 55.25%. The company has reported no revenue for several quarters, and its forward P/E ratio is 0, indicating uncertainty about future earnings. The main risk is the negative net income trend, with losses reaching -$3.56 million in Q4 2025. Therefore, while there are signs of potential recovery, the lack of revenue and ongoing losses suggest a cautious approach is warranted.